Eyes on the target: a Back to School podcast preview

Can the era of human first, causal biology and personalized medicine reshape drug discovery?

In this year’s series of Back to School essays, BioCentury’s editors ask whether the era of human-first, causal biology and personalized medicine can reshape drug discovery to solve the weakest link in biotech — translation to the clinic. On a special edition of the BioCentury This Week podcast, the three authors of BioCentury’s 32nd Back to School edition, Editor in Chief Simone Fishburn, Executive Editor Selina Koch, and Executive Director of Biopharma Intelligence Lauren Martz, discuss how industry can solve its biggest bottleneck.

The editors zero in on inflammation and immunology, including how immunoproteomics is upstaging genomics in I&I target discovery, and neurology, where genomics still has more to give and human-derived model systems are becoming workhorses of validation work. Finally, they discuss the thread that runs through it all — precision medicine — and how biomarkers can help validate targets while bringing precision medicine to I&I and neurology.